446 related articles for article (PubMed ID: 37534876)
41. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
medRxiv; 2021 Dec; ():. PubMed ID: 34909794
[TBL] [Abstract][Full Text] [Related]
42. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
43. The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes.
Degli Esposti L; Perrone V; Sangiorgi D; Andretta M; Bartolini F; Cavaliere A; Ciaccia A; Dell'orco S; Grego S; Salzano S; Ubertazzo L; Vercellone A; Gatti D; Fassio A; Viapiana O; Rossini M; Adami G
J Bone Miner Res; 2021 Nov; 36(11):2177-2183. PubMed ID: 34405441
[TBL] [Abstract][Full Text] [Related]
44. Return-to-work, disabilities and occupational health in the age of COVID-19.
Godeau D; Petit A; Richard I; Roquelaure Y; Descatha A
Scand J Work Environ Health; 2021 Jul; 47(5):408-409. PubMed ID: 34003294
[TBL] [Abstract][Full Text] [Related]
45. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
46. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
47. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
48. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
49. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
50. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
52. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
53. A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.
Anisul M; Shilts J; Schwartzentruber J; Hayhurst J; Buniello A; Shaikho Elhaj Mohammed E; Zheng J; Holmes M; Ochoa D; Carmona M; Maranville J; Gaunt TR; Emilsson V; Gudnason V; McDonagh EM; Wright GJ; Ghoussaini M; Dunham I
Elife; 2021 Aug; 10():. PubMed ID: 34402426
[TBL] [Abstract][Full Text] [Related]
54. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
55. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
56. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
[TBL] [Abstract][Full Text] [Related]
57. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
58. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
[TBL] [Abstract][Full Text] [Related]
59. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
60. Bisphosphonates for steroid-induced osteoporosis.
Allen CS; Yeung JH; Vandermeer B; Homik J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
